Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genfit S.A. ADR (NQ: GNFT )

4.350 -0.090 (-2.03%)
Streaming Delayed Price Updated: 11:16 AM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Genfit S.A. ADR

< Previous 1 2 3 4 Next >
FDA Fast-Tracks Ipsen And Genfit's New Liver Disease Treatment, Iqirvo
The U.S. FDA has granted accelerated approval for Iqirvo, a novel drug from Ipsen SA and Genfit SA, designed for treating primary biliary cholangitis (PBC). This approval, based on the drug's ability... 
Via Benzinga
Exposures Product Safety
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Analyst Expectations for Genfit's Future
Via Benzinga
Genfit To Buy This Swiss Firm Expanding Its Portfolio in Liver Diseases
Via Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For April 4, 2024
Companies Reporting Before The Bell • Conagra Brands (NYSE:CAG) is likely to report quarterly earnings at $0.65 per share on revenue of $3.01 billion. 
Via Benzinga
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
The company is working on the first treatment that could make a difference in the itching associated with a liver disease. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why CymaBay, With 172% Growth This Year, Just Surged For A Second Day Running
The company is working on a treatment for a liver disease that can cause severe itching. 
Via Investor's Business Daily
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of  
Via Benzinga
Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class
Friday, CymaBay Therapeutics Inc's (NASDAQ: CBAY) competitors Genfit SA (NASDAQ: GNFT) and Ipsen SA (OTC:  
Via Benzinga
Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)  
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug
Following the FDA rejection, Intercept will restructure to focus on rare liver diseases. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga
Earnings Scheduled For April 13, 2023
Companies Reporting Before The Bell • Northern Technologies (NASDAQ:NTIC) is estimated to report quarterly earnings at $0.18 per share on revenue of $20.40 million. 
Via Benzinga
The 7 Best Biotech Stocks to Buy for February 2023
Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million. 
Via Benzinga
Earnings Scheduled For September 28, 2022
Companies Reporting Before The Bell • Lilium (NASDAQ:LILM) is expected to report earnings for its second quarter. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Genfit (NASDAQ:GNFT) shares increased by 27.4% to $5.12 during Thursday's after-market session. The market value of their outstanding shares is at $255.0 million. 
Via Benzinga
US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade on Wednesday after recording sharp losses on Tuesday following the release of inflation data for August. All the three major... 
Via Benzinga
BRP, Conformis And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
Via Benzinga
GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma. 
Via Benzinga
Analyzing Genfit's Short Interest
Genfit's (NASDAQ:GNFT) short percent of float has risen 15.09% since its last report. The company recently reported that it has 296 thousand shares sold short, which is 0.61%... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.